Literature DB >> 25261332

Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues.

A Comunello1, F Dassie, C Martini, E De Carlo, R Mioni, M Battocchio, A Paoletta, F Fallo, R Vettor, P Maffei.   

Abstract

BACKGROUND: Cardiovascular complications, including arrhythmias and cardiac sudden death, are the most common causes of enhanced mortality in acromegaly. However, few data are available on cardiac autonomic functions and sympathovagal balance in acromegalic patients.
OBJECTIVE: The aim of this study was to investigate both the time and frequency domain parameters of Heart Rate Variability (HRV), in order to characterize the cardiac autonomic functions in patients affected by acromegaly. This study correlated anthropometric, metabolic, echocardiographic parameters and blood pressure with those relating to HRV, to identify the main factors responsible for the HRV related alterations possibly present. We also aimed to analyze the effects of the treatment with somatostatin analogues (SSAs) on HRV.
MATERIALS AND METHODS: This study enrolled 47 acromegalic patients (23 males, age 49.1 ± 13.5 years) and 37 (13 males) age matched (52.3 ± 13.3 years) healthy subjects. All participants underwent 12-lead 24 h ECG Holter recordings and a HRV analysis of the ECG tracings was performed. The parameters obtained from the time domain analysis of HRV included pNN50, SDNN, SDNN index, SDANN and RMSSD. The power spectral analysis of HRV was obtained by summing powers of the LF (low frequency) and the HF (high frequency) band. Sympathovagal balance was estimated by calculating the LF/HF ratio during 24 h and 15 min of clinostatism. The HRV of 28 acromegalic patients was studied before and after SSAs treatment.
RESULTS: Acromegalic patients showed significantly lower SDNN and SDANN compared to controls. Diabetic and non-diabetic acromegalic patients showed decreased SDNN and SDANN, when compared to healthy subjects. Diabetic acromegalic patients had a lower LF/HF ratio during 24 h when compared to non-diabetic acromegalic patients. Similar results were obtained analyzing patients affected by acromegaly and impaired glucose tolerance. SDNN and SDANN were lowered by hypertension in the acromegalic population, when compared to controls, and hypertensive acromegalic patients also displayed a decreased LF/HF ratio during 24 h when compared to normotensive acromegalic subjects. Patients with ventricular arrhythmias in Lown classes 3-5 showed a decreased SDANN compared to patients in Lown class 0-2. The treatment with SSAs was able to ameliorate all the time domain parameters of HRV, without altering the 24 h LF/HF ratio.
CONCLUSION: Cardiac autonomic functions and sympathovagal balance are altered in patients affected by acromegaly and could be ameliorated by SSAs therapy. HRV analysis allows an estimation of the autonomic sympathovagal balance and may be a useful clinical tool for the cardiac risk stratification in acromegalic patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25261332     DOI: 10.1007/s11102-014-0605-6

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  59 in total

Review 1.  Cardiovascular function in acromegaly.

Authors:  R N Clayton
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

Review 2.  Beat to beat variability in cardiovascular variables: noise or music?

Authors:  M L Appel; R D Berger; J P Saul; J M Smith; R J Cohen
Journal:  J Am Coll Cardiol       Date:  1989-11-01       Impact factor: 24.094

3.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

4.  Arrhythmia profile in acromegaly.

Authors:  G Kahaly; K V Olshausen; S Mohr-Kahaly; R Erbel; S Boor; J Beyer; J Meyer
Journal:  Eur Heart J       Date:  1992-01       Impact factor: 29.983

5.  Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients.

Authors:  Letizia Maria Fatti; Massimo Scacchi; Elisabetta Lavezzi; Francesca Pecori Giraldi; Martina De Martin; Paola Toja; Georgios Michailidis; Marco Stramba-Badiale; Francesco Cavagnini
Journal:  Clin Endocrinol (Oxf)       Date:  2006-11       Impact factor: 3.478

6.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

7.  Sympathovagal imbalance in acromegalic patients.

Authors:  Eugenia Resmini; Massimo Casu; Vittoriana Patrone; Giovanni Murialdo; Federico Bianchi; Massimo Giusti; Diego Ferone; Francesco Minuto
Journal:  J Clin Endocrinol Metab       Date:  2005-11-01       Impact factor: 5.958

8.  Determinants of clinical outcome and survival in acromegaly.

Authors:  C Rajasoorya; I M Holdaway; P Wrightson; D J Scott; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-07       Impact factor: 3.478

Review 9.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

10.  Mortality due to sudden infant death syndrome in Northern Italy, 1990-2000: a baseline for the assessment of prevention campaigns.

Authors:  Cristina Montomoli; Maria C Monti; Marco Stramba-Badiale; Alessandra Marinoni; Nives Foglieni; Vittorio Carreri; Maurizio Amigoni; Peter J Schwartz
Journal:  Paediatr Perinat Epidemiol       Date:  2004-09       Impact factor: 3.980

View more
  7 in total

Review 1.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

Review 2.  Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?

Authors:  M Parolin; F Dassie; R Vettor; R P Steeds; P Maffei
Journal:  J Endocrinol Invest       Date:  2020-07-06       Impact factor: 4.256

Review 3.  Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.

Authors:  Federico Gatto; Claudia Campana; Francesco Cocchiara; Giuliana Corica; Manuela Albertelli; Mara Boschetti; Gianluigi Zona; Diego Criminelli; Massimo Giusti; Diego Ferone
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

Review 4.  Advances in Research on the Cardiovascular Complications of Acromegaly.

Authors:  Han Yang; Huiwen Tan; He Huang; Jianwei Li
Journal:  Front Oncol       Date:  2021-04-02       Impact factor: 6.244

5.  Increased Short-Term Beat-To-Beat Variability of QT Interval in Patients with Acromegaly.

Authors:  Andrea Orosz; Éva Csajbók; Csilla Czékus; Henriette Gavallér; Sándor Magony; Zsuzsanna Valkusz; Tamás T Várkonyi; Attila Nemes; István Baczkó; Tamás Forster; Tibor Wittmann; Julius Gy Papp; András Varró; Csaba Lengyel
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

Review 6.  Heart rate variability in type 2 diabetes mellitus: A systematic review and meta-analysis.

Authors:  Thomas Benichou; Bruno Pereira; Martial Mermillod; Igor Tauveron; Daniela Pfabigan; Salwan Maqdasy; Frédéric Dutheil
Journal:  PLoS One       Date:  2018-04-02       Impact factor: 3.240

7.  Heart Rate Variability in Postoperative Patients with Nonfunctioning Pituitary Adenoma.

Authors:  Jeonghoon Ha; Hansang Baek; Chaiho Jeong; Minsoo Yeo; Seung-Hwan Lee; Jae Hyoung Cho; Ki-Hyun Baek; Moo Il Kang; Dong-Jun Lim
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.